Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;5(4):1143-1146.
doi: 10.3892/etm.2013.933. Epub 2013 Jan 30.

A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells

Min Fan  1 , Xinying Li, Wei Jiang, Yun Huang, Jingdong Li, Zhiming Wang
Affiliations

A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells

Min Fan et al. Exp Ther Med. 2013 Apr.

Abstract

Papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) is a newly identified non-coding RNA, which is highly thyroid-specific. Dramatic downregulation in thyroid cancers suggests its potential roles in the occurrence and development of thyroid tumors. The present study aimed to investigate the effects of PTCSC3 on the biological features of thyroid cancer cells and to explore its possible function as a competing endogenous RNA to bind with miRNAs. Constructs containing the long non-coding RNA, PTCSC3, were transfected into various thyroid cancer cell lines (BCPAP, FTC133 and 8505C). Cell growth, cell cycle transition and apoptosis were measured by MTT assay and flow cytometry. In silico analysis was performed to identify the binding site of PTCSC3 for target miRNAs. Additionally, detection of putative miRNA by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in thyroid cancer cells transfected with PTCSC3 was determined to confirm the interaction. Following transfection with PTCSC3, all three thyroid cancer cells originating from various pathological types of thyroid cancers demonstrated significant growth inhibition, cell cycle arrest and increased apoptosis. The top 20 miRNAs to have a potential interaction with PTCSC3 were identified, out of which miR-574-5p was selected to further confirm the inverse correlation with PTCSC3 in thyroid cancer cells in vitro. In the present study, PTCSC3 as a tumor suppressor was investigated as a competing endogenous RNA for miR-574-5p.

Keywords: miR-574-5p; papillary thryoid susceptibility candidate 3; thyroid cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MTT assay. BCPAP, FTC133 and 8505C thyroid cancer cells (transfected with empty plasmid) had higher absorptance values at 48, 72 and 96 h compared with those transfected with PTCSC3 (*P<0.01). PTCSC3, papillary thyroid susceptibility candidate 3.
Figure 2
Figure 2
Two possible binding sites between lncRNA PTCSC3 and miR-574-5p. The upper lines are the sequence of miR-574-5p and the lower lines are the sequence of lncRNA PTCSC3. lnc, long non-coding; PTCSC3, papillary thyroid susceptibility candidate 3.
Figure 3
Figure 3
miR-574-5p expression in thyroid cell lines (BCPAP, FTC133 and 8505C) transfected with PTCSC3. PTCSC3, papillary thyroid susceptibility candidate 3.
See this image and copyright information in PMC

References

    1. Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983–2007. Asia Pac J Public Health. 2012 Mar 16; (Epub ahead of print). - PubMed
    1. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115:3801–3807. - PubMed
    1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–2167. - PubMed
    1. Li X, Abdel-Mageed AB, Kandil E. BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med. 2012;5:310–315. - PMC - PubMed
    1. Li X, Abdel-Mageed AB, Mondal D, Kandil E. The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid. 2012 Aug 13; (Epub ahead of print). - PubMed